Zacks.com on MSN14h
Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug
The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of ...
£2,000 invested in penny share Angle just 3 months ago would now be worth…
Angle (LON:AGL) is a small share that's skyrocketed in recent weeks. Why does this investor hold the high-risk penny stock?
The Pharma Letter18h
BRIEF—EC calls for update on regulatory review of lecanemab
Japan’s Eisai and US partner Biogen have announced today update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab (trade name Leqembi) as a treatment for early ...
24/7 Wall St. on MSN6h
The Dow Jones Industrials Are Winning 2025: 4 Highest-Yielding Dogs of the Dow Are Steals
The Dow Jones industrial average (DJIA) is a price-weighted average of 30 blue-chip U.S. stocks, often industry leaders. It ...
lifesciencesweden.se17h
Life Science Trends 2025 – Part 4 Neuro
New Alzheimer's drugs are beginning to be used in Sweden, more deals in the neuro sector are expected, and tools for deliver ...